| Generic Name |
Encorafenib |
| Brand Name |
Braftovi® |
| Payment Category |
Medicare Part D |
| Year Introduced |
2018 |
| Type of Drug |
Kinase inhibitor |
| Manufacturer |
Array Biopharma |
| Medical Affairs Questions (date verified) |
844.792.7729 |
| Coverage & Reimbursement Questions |
866.277.2927 |
FDA-Approved Indication(s)
- Indicated, 1) in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test, and 2) in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy. (4/9/20)
|
| Approved Indication(s) with Orphan Drug Status |
(In combination with binimetinib) Treatment of Stage III-IV melanoma positive for BRAF mutation |
| ICD-10 Code(s) for Labeled Indication(s) |
Melanoma [C43.xx]; Colorectal cancer [C18x, C19, C20, or C21.x, dependent on location] |
